Anti-HIV-1 clade B gp120 Recombinant Antibody (A32) (CAT#: MRO-022LC)

Figure 1. SDS-PAGE and Western blot analysis of unfractionated and FPLC-fractionated A32-rgp120 complexes.

Liao, H. X., Alam, S. M., Mascola, J. R., Robinson, J., Ma, B., Montefiori, D. C., ... & Haynes, B. F. (2004). Immunogenicity of constrained monoclonal antibody A32-human immunodeficiency virus (HIV) Env gp120 complexes compared to that of recombinant HIV type 1 gp120 envelope glycoproteins. Journal of virology, 78(10), 5270-5278.

Figure 1 Anti-HIV-1 clade B gp120 Recombinant Antibody (MRO-022LC) in WB

Western blot analysis was performed with 1 µg (lane 1), 2 µg(lane 2) recombinant HIV-1 Env onto a 12% Tris-HCl polyacrylamide gel. Proteins were transferred to a CN membrane and blocked with 5% skim milk for at least 1 hour. Membranes were probed with MRO-022LC at a dilution of 1:250 overnight at 4°C on a rocking platform. Then probed with Goat anti-Human IgG HRP secondary antibody at a dilution of 1:2,000 for one hour. Chemiluminescent was detected.

Figure 2 Anti-HIV-1 clade B gp120 Recombinant Antibody (MRO-022LC) in Dot Blot

Dot Blot analysis of MRO-022LC was performed by coating with HIV-1 Env antigen.
MRO-022LC incubation concentration: 4 ng/μL.
The secondary antibody: HRP-Anti-Human IgG (H+L)

Figure 3 Anti-HIV-1 clade B gp120 Recombinant Antibody (MRO-022LC) in ELISA

ELISA analysis of MRO-022LC was performed by coating with recombinant HIV-1 Env antigen. Then blocked with BSA, and incubated with MRO-022LC at a starting concentration of 2.5 µg/mL. The HRP-conjugated goat anti-human IgG was used as a secondary antibody. Detection was performed using TMB substrate and stopped with sulfuric acid. The absorbances were read on a spectrophotometer at 450 nm.